28m
XORTX Therapeutics Inc.: XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results